Biodegradable bimatoprost implant gains FDA approval

• Posted on: Mar 6 2020
• By: Saratoga Opthalmology
• Leave a response

Allergan’s bimatoprost implant (Durysta) is now the first approved intracameral, sustained-release therapy for lowering IOP in patients with open-angle glaucoma or ocular hypertension.
Source: AAO

Posted in: Uncategorized